First National Trust Co Sells 823 Shares of Eli Lilly and Company $LLY

First National Trust Co lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 32,588 shares of the company’s stock after selling 823 shares during the period. Eli Lilly and Company comprises approximately 0.9% of First National Trust Co’s investment portfolio, making the stock its 22nd largest holding. First National Trust Co’s holdings in Eli Lilly and Company were worth $25,403,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Purkiss Capital Advisors LLC raised its stake in shares of Eli Lilly and Company by 80.3% during the 2nd quarter. Purkiss Capital Advisors LLC now owns 1,037 shares of the company’s stock worth $808,000 after purchasing an additional 462 shares in the last quarter. Clark Asset Management LLC raised its stake in shares of Eli Lilly and Company by 7.5% during the 2nd quarter. Clark Asset Management LLC now owns 662 shares of the company’s stock worth $516,000 after purchasing an additional 46 shares in the last quarter. Motley Fool Asset Management LLC raised its position in Eli Lilly and Company by 7.2% during the second quarter. Motley Fool Asset Management LLC now owns 49,197 shares of the company’s stock worth $38,351,000 after acquiring an additional 3,319 shares in the last quarter. Taylor Financial Group Inc. raised its position in Eli Lilly and Company by 3.0% during the second quarter. Taylor Financial Group Inc. now owns 3,493 shares of the company’s stock worth $2,723,000 after acquiring an additional 102 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Eli Lilly and Company by 16.4% during the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 219,814 shares of the company’s stock worth $171,352,000 after acquiring an additional 30,900 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on LLY shares. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Stock Up 0.0%

Eli Lilly and Company stock opened at $825.74 on Tuesday. The stock has a market cap of $781.53 billion, a P/E ratio of 53.97, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company’s 50-day moving average price is $770.54 and its two-hundred day moving average price is $769.08.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last quarter. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.